Health Trials

Study of XB010 in Subjects With Solid Tumors

ConditionsLocally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell CancerNSCLC (Non-small Cell Lung Cancer)Hormone-receptor-positive Breast CancerTriple Negative Breast Cancer (TNBC)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorExelixis

About this trial

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Eligibility criteria

Qualifiers

Age 18 years or older on the day of consent.

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

Adequate organ and marrow function.

Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • XB010
  • Pembrolizumab

Treatment groups

396 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Exelixis

Lead sponsor

Source ClinicalTrials.gov